Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7160559	JANSSEN PHARMS	Controlled release galantamine composition	Dec, 2019 (4 years ago)

Razadyne Er is owned by Janssen Pharms.

Razadyne Er contains Galantamine Hydrobromide.

Razadyne Er has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Razadyne Er are:

Razadyne Er was authorised for market use on 01 April, 2005.

Razadyne Er is available in capsule, extended release;oral dosage forms.

The generics of Razadyne Er are possible to be released after 20 December, 2019.

Market Authorisation Date: 01 April, 2005

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
8 mg	02 Mar, 2006	1	15 Sep, 2008	20 Dec, 2019	Eligible
16 mg and 24 mg	11 Mar, 2006	1	15 Sep, 2008	20 Dec, 2019	Eligible

Strength	Dosage	Availability
EQ 16MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
EQ 8MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
EQ 24MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

Razadyne Er patents expiration